Category - Developments

Developments

Positive results from Perimeter’s B-Series OCT with ImgAssist AI 2.0 pivotal trial presented at ASBrS 2025

Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) announced that detailed, positive results from the pivotal trial evaluating the use of its next-generation B-Series OCT with ImgAssist AI 2.0 for intraoperative...

May 5, 2025

Developments

electroCore acquires NeuroMetrix gaining access to Quell platform

electroCore (NASDAQ:ECOR) announced it has completed the merger with NeuroMetrix (NASDAQ:NURO), expanding its portfolio to include Quell Fibromyalgia Solution, strengthening its commercial reach, and positioning the...

May 2, 2025

Developments

Vaccine publishes study demonstrating benefits of PharmaJet’s Tropis needle-free system

Closely held PharmaJet announced the publication of a study in the top-tier journal Vaccine, which demonstrates the benefits of the company’s Tropis needle-free system compared to needle and syringe (N/S) for...

May 1, 2025

Developments

Profound reports positive perioperative data from randomized CAPTAIN trial comparing TULSA with Robotic Prostatectomy; Lake Street analyst suggests trial data will be well received by payors

Profound Medical (NASDAQ:PROF; TSX:PRN) announced initial perioperative data from its Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the TULSA procedure with radical prostatectomy (RP) in men...

April 30, 2025

Developments

Immunic unveils positive data from Phase 2 trial of IMU-838 in progressive MS

Immunic (NASDAQ:IMUX) announced positive Phase 2 CALLIPER data demonstrating its nuclear receptor related 1 (Nurr1) activator—vidofludimus calcium (IMU-838)—reduced the risk of progressive multiple sclerosis (PMS)...

April 30, 2025

Developments

Polyrizon reports positive safety study of allergy blocker

Polyrizon (NASDAQ:PLRZ) announced the successful preliminary safety study of a formulation of its PL-14 Allergy Blocker, advancing the product’s development path. According to Polyrizon, the study, designed to assess...

April 25, 2025

Developments

Ekso names Bionic P&O as first Ekso Indego Personal distributor within the orthotics and prosthetics industry

Ekso Bionics Holdings (NASDAQ:EKSO) announced it has selected Bionic Prosthetics & Orthotics Group (Bionic P&O) as a non-exclusive distributor of its Ekso Indego Personal device—the alliance marking Ekso’s first...

April 23, 2025

Developments

FDA clears Aclaris’ IND application for ATI-052 trial

Aclaris Therapeutics (NASDAQ:ACRS) announced that the FDA has cleared its Investigational New Drug (IND) application for a Phase 1a/1b trial of ATI-052—expected to launch in Q2 of this year. According to Aclaris, the...

April 22, 2025

Developments

USPTO grants Atossa patents strengthening breast cancer treatment portfolio

Atossa Therapeutics (NASDAQ:ATOS) announced that the USPTO has granted a new patent for enteric oral formulations comprising (Z)-endoxifen, including methods of treating patients. According to Atossa, the patent...

April 22, 2025

Developments

PharmaJet to present insights from DNA cancer vaccine partner trials at WVC 2025

Closely held PharmaJet announced it will present insights from several DNA cancer vaccine partner trials using PharmaJet’s Precision Delivery Systems at the World Vaccine Congress (WVC) on April 23, 2025 at 12:25 pm ET...

April 17, 2025

Category - Developments

Subscribe